News

GLP-1 race heats up: Where Eli Lilly stands after weak trial data

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much ...
Fierce Pharma2d

Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Lilly's obesity pill lags Novo's Wegovy injection in key trial

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...